CA2324254C - Composition a liberation prolongee contenant un polymre amorphe - Google Patents

Composition a liberation prolongee contenant un polymre amorphe Download PDF

Info

Publication number
CA2324254C
CA2324254C CA002324254A CA2324254A CA2324254C CA 2324254 C CA2324254 C CA 2324254C CA 002324254 A CA002324254 A CA 002324254A CA 2324254 A CA2324254 A CA 2324254A CA 2324254 C CA2324254 C CA 2324254C
Authority
CA
Canada
Prior art keywords
particle
particles
biocompatible polymer
pharmaceutical substance
antisolvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002324254A
Other languages
English (en)
Other versions
CA2324254A1 (fr
Inventor
Theodore W. Randolph
Mark C. Manning
Richard F. Falk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Technology Corp
Original Assignee
University of Technology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Technology Corp filed Critical University of Technology Corp
Publication of CA2324254A1 publication Critical patent/CA2324254A1/fr
Application granted granted Critical
Publication of CA2324254C publication Critical patent/CA2324254C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Botany (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition permettant la libération prolongée d'une substance pharmaceutique. Cette composition contient un polymère biocompatible hautement amorphe dans un complexe d'ions hydrophobe associé à un matériau amphiphile. L'invention concerne également un procédé utilisant un antisolvant comprimé pour fabriquer la composition, différentes formes de produit incorporant la composition, et diverses utilisations convenant à la composition.
CA002324254A 1998-03-18 1999-03-18 Composition a liberation prolongee contenant un polymre amorphe Expired - Lifetime CA2324254C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7839098P 1998-03-18 1998-03-18
US60/078,390 1998-03-18
PCT/US1999/006198 WO1999047543A2 (fr) 1998-03-18 1999-03-18 Composition a liberation prolongee contenant un polymre amorphe

Publications (2)

Publication Number Publication Date
CA2324254A1 CA2324254A1 (fr) 1999-09-23
CA2324254C true CA2324254C (fr) 2005-01-04

Family

ID=22143753

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002324254A Expired - Lifetime CA2324254C (fr) 1998-03-18 1999-03-18 Composition a liberation prolongee contenant un polymre amorphe

Country Status (5)

Country Link
EP (1) EP1073419A4 (fr)
JP (1) JP2002506876A (fr)
AU (1) AU3108299A (fr)
CA (1) CA2324254C (fr)
WO (1) WO1999047543A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2815540B1 (fr) † 2000-10-19 2005-06-10 Separex Sa Procede de fabrication de tres fines particules constituees d'un principe insere dans une molecule hote
JP2005514326A (ja) * 2001-07-10 2005-05-19 コリクサ コーポレイション ミクロスフェア中に封入されたタンパク質およびアジュバントを送達するための組成物および方法
GB0216780D0 (en) * 2002-07-19 2002-08-28 Bradford Particle Design Ltd Methods of particle formation
EP1452177A1 (fr) * 2003-02-27 2004-09-01 Boehringer Ingelheim International GmbH Compositions pharmaceutiques contenant du laurylsulfate de sodium comme agent qui masque l'amertume
EP1727520A2 (fr) 2003-12-09 2006-12-06 Medcrystalforms, Llc Procede de preparation de cocristaux a phase mixte avec des agents actifs
US8956602B2 (en) 2006-12-05 2015-02-17 Landec, Inc. Delivery of drugs
US8399007B2 (en) 2006-12-05 2013-03-19 Landec Corporation Method for formulating a controlled-release pharmaceutical formulation
US8114883B2 (en) 2007-12-04 2012-02-14 Landec Corporation Polymer formulations for delivery of bioactive materials
WO2009100222A1 (fr) 2008-02-08 2009-08-13 Qps Llc Compositions non polymères pour l'administration contrôlée de médicament
US20160175313A1 (en) * 2013-08-06 2016-06-23 Dongkook Pharmaceutical Co., Ltd., Entecavir microspheres and pharmaceutical composition for parenteral administration containing same
WO2016039678A1 (fr) * 2014-09-10 2016-03-17 Double Bond Pharmaceuticals Ab Administration ciblée de médicaments hydrophiles
CN109069423A (zh) * 2016-03-07 2018-12-21 双键医药品股份公司 亲水性药物的肺部靶向递送

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4582820A (en) * 1982-12-23 1986-04-15 Research Corporation Orally administered biologically active peptides and proteins
ATE37983T1 (de) * 1982-04-22 1988-11-15 Ici Plc Mittel mit verzoegerter freigabe.
CH683149A5 (fr) * 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
AU5171293A (en) * 1992-10-14 1994-05-09 Regents Of The University Of Colorado, The Ion-pairing of drugs for improved efficacy and delivery
AU695207B2 (en) * 1995-03-28 1998-08-06 Fidia Farmaceutici S.P.A. Nanospheres comprising a biocompatible polysaccharide
WO1997038698A1 (fr) * 1996-04-18 1997-10-23 University Technology Corporation Procedes pour le traitement de troubles de l'oreille interne et moyenne

Also Published As

Publication number Publication date
WO1999047543A3 (fr) 1999-11-04
WO1999047543A2 (fr) 1999-09-23
CA2324254A1 (fr) 1999-09-23
JP2002506876A (ja) 2002-03-05
EP1073419A4 (fr) 2009-03-25
AU3108299A (en) 1999-10-11
EP1073419A2 (fr) 2001-02-07

Similar Documents

Publication Publication Date Title
US6613358B2 (en) Sustained-release composition including amorphous polymer
US5981474A (en) Solubilization of pharmaceutical substances in an organic solvent and preparation of pharmaceutical powders using the same
CA2324254C (fr) Composition a liberation prolongee contenant un polymre amorphe
US20020032166A1 (en) Biocompatible cationic detergents and uses therefor
KR101288729B1 (ko) 약물 전달용 중합체성 마이셀
US8333959B2 (en) Ex-vivo application of solid microparticulate therapeutic agents
WO1998010649A9 (fr) Detergents cationiques biocompatibles et leurs utilisations
EP1416917B1 (fr) Dispersion aqueuse comprenant des nanoparticules stables d'un triglyceride a chaine moyenne (mtc) insoluble dans l'eau actif et d'un triglyceride a chaine moyenne de type excipient
US20040247624A1 (en) Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility
AU2020253560A1 (en) Improved conjugation linkers
JP2002530323A (ja) ポリアミノ酸ベースの粒子およびその製造方法
AU2215800A (en) Therapeutic delivery using compounds self-assembled into high axial ratio microstructures
JP2013518097A (ja) 肺高血圧を予防および治療するための組成物および方法
US7776360B2 (en) (Polyalkoxy)sulfonate surface modifiers
WO2006118327A1 (fr) Lipide de type acide aminé cationique
EP2138192A1 (fr) Agent utilisé pour améliorer la résistance d'un liposome contre un constituant biologique et liposome modifié avec ledit agent
JP2002514215A (ja) 治療薬の徐放送達のための生分解性微粒子
CN107847436B (zh) 凝胶组合物和凝胶组合物的制造方法
CN115073552A (zh) 一种多肽、水凝胶及其用途
JP2010065067A (ja) 粒子およびその製造方法、ならびにゲル
CN107638385B (zh) Css-peg-grgds纳米颗粒及其制备方法与在静脉止血中的应用
WO2004006893A1 (fr) Procede de precipitation de particules au moyen d'antisolvants presque critiques et supercritiques
CN115521603A (zh) 一种可原位相转变形成凝胶的组合物及其用途
Matsumoto et al. Testosterone delivery using glutamide-based complex high axial ratio microstructures

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20190318